[Up-and-coming therapeutics for osteoporosis]
1Toranomon Hospital Endocrine Center.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 22, 2011
Summary
Established and emerging osteoporosis drugs offer fracture prevention. Emerging therapeutics like cathepsin K inhibitors require careful evaluation of safety and efficacy alongside current treatments.
Area of Science:
- Bone metabolism research
- Pharmacological interventions for bone health
Context:
- Osteoporosis poses a significant fracture risk, particularly in postmenopausal women.
- Current treatments include bisphosphonates, SERMs, teriparatide, and denosumab.
Purpose:
- To review established and emerging therapeutics for osteoporosis.
- To highlight the importance of evaluating the safety and efficacy of new treatments.
Summary:
- Several drugs are established for preventing osteoporotic fractures.
- Emerging treatments include cathepsin K inhibitors, anti-sclerostin antibodies, and eldecalcitol.
- Assessing the safety and efficacy of novel osteoporosis drugs is crucial.
Impact:
- Provides an overview of current and future osteoporosis treatment options.
- Emphasizes the need for rigorous evaluation of new drug candidates.
- Informs clinicians and researchers about the evolving landscape of osteoporosis therapy.
